Brief: Sandoz Reports Q1 Net Sales Of $2,756 Mln
April 29 (Reuters) - SANDOZ GROUP AG SDZ.S: REPORTS STRONG BIOSIMILARS GROWTH IN Q1 2026; FULL-YEAR 2026 GUIDANCE CONFIRMED Q1 2026 NET SALES $2,756 MILLION, UP 11% YEAR-ON-YEAR CONFIRMS FULL-YEAR 2026 GUIDANCE Q1 NORTH AMERICA NET SALES UP BY 12% AT CC Q1 BIOSIMILAR NET SALES UP BY 18% AT CC Source text: ID:nEQ4GVymqa Further company coverage: SDZ.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 587785269;))
Recent news on Sandoz AG
See all newsPfizer dismissed from US states' drug price-fixing lawsuit (updated)
Pfizer dismissed from US states' drug price-fixing lawsuit
Factbox: Major investment pledges at Choose France summit
Press Digest: Financial Times - June 1
Media: Sandoz warns cheap Chinese imports threaten Europe’s antibiotic supply- FT